

## Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

Lauper K, Mongin D, Iannone F, *et al.* Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. *RMD Open* 2018;4:e000809. doi: 10.1136/rmdopen-2018-000809.

The article has been corrected since it was published online. The values in the second row “Total patient-years” of table 1 have been amended and the supplement file has been updated to support the same.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) [year]. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*RMD Open* 2019;5:e000809corr1. doi:10.1136/rmdopen-2018-000809corr1

